Valneva SE, a vaccine specialist created by a merger in 2013, is the only drugmaker in the U.S. and Europe developing an inactivated shot against the SARS-CoV-2 virus. The approach uses a sample of the coronavirus that has been killed to stimulate an immune response without causing the disease. The approach has been used for decades with inoculations for polio and hepatitis A.